Journal
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
Volume 27, Issue -, Pages -Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/1076029621999099
Keywords
COVID-19; immunothrombosis; D dimer; interleukin 6; interleukin 8; PAI-1; P-selectin; von Willebrand factor
Categories
Funding
- Consejo Nacional de Ciencia y Tecnologia [2020-1, 312999]
- CONACYT-Mexico
Ask authors/readers for more resources
In hospitalized COVID-19 patients, alterations in inflammatory and coagulation biomarkers are closely related to poor prognosis, with significantly elevated levels of D-dimer and PAI-1 in severe cases, along with distinct differences in inflammatory markers between non-severe patients and those who succumbed to the disease.
Among COVID-19 hospitalized patients, high incidence of alterations in inflammatory and coagulation biomarkers correlates with a poor prognosis. Comorbidities such as chronic degenerative diseases are frequently associated with complications in COVID-19 patients. The aim of this study was to evaluate inflammatory and procoagulant biomarkers in COVID-19 patients from a public hospital in Mexico. Blood was sampled within the first 48 h after admission in 119 confirmed COVID-19 patients that were classified in 3 groups according to oxygen demand, evolution and the severity of the disease as follows: 1) Non severe: nasal cannula or oxygen mask; 2) Severe: high flow nasal cannula and 3) Death: mechanical ventilation eventually leading to fatal outcome. Blood samples from 20 healthy donors were included as a Control Group. Analysis of inflammatory and coagulation biomarkers including D-dimer, interleukin 6, interleukin 8, PAI-1, P-selectin and VWF was performed in plasma. Routine laboratory and clinical biomarkers were also included and compared among groups. Concentrations of D-dimer (14.5 +/- 13.8 mu g/ml) and PAI-1 (1223 +/- 889.6 ng/ml) were significantly elevated in severe COVID-19 patients (P < 0.0001). A significant difference was found in interleukin-6, PAI-1 and P-selectin in non-severe and healthy donors when compared to Severe COVID-19 and deceased patients (P < 0.001). VWF levels were also significantly different between severe patients (153.5 +/- 24.3 UI/dl) and non-severe ones (133.9 +/- 20.2 UI/dl) (P < 0.0001). WBC and glucose levels were also significantly elevated in patients with Severe COVID-19. Plasma concentrations of all prothrombotic biomarkers were significantly higher in patients with a fatal outcome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available